Rise of AI continues to re-write life sciences IP strategies in 2022
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
Lighting firm Signify and panel-maker Samsung Display each acquired portfolios from one of Japan’s leading IP dealmakers last month
Saturday Opinion: Technology solutions that have helped the world through the pandemic would look very different absent a sophisticated IP licensing ecosystem, argues Dolby GC Andy Sherman
Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again
19 October 2021
Co-published - IP transfers in the sector happen for many reasons but one of the primary ones is to create additional value from the assets concerned
18 October 2021
Yangtze Memory Technologies Co, based in Wuhan, is just five years old but has emerged as the country’s memory chip champion
14 October 2021
Transaction marks first outside patent acquisition since company was spun out from Huawei last year
13 October 2021
Saturday Opinion: A memorable two days in the Irish capital showed definitively that face-to-face trumps video and allowed for some detailed debate on key topics
09 October 2021
Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.
07 October 2021
Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios
04 October 2021
M&A may be stagnant, but innovators are receiving larger upfront payments for partnership agreements
01 October 2021
Luxshare has pursued Chinese legal challenges and gotten more involved in dealmaking in response to its first serious patent litigation threat, filed in the US last year
30 September 2021
Experts embrace the Leahy/Tillis bill’s aims, but warn it could create unwelcome, new overhead costs and administrative burdens
29 September 2021
Get unlimited access to all IAM content